Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer

References

• Douaiher J, Ravipati A, Grams B, Chowdhury S, Alatise O, Are C. Colorectal cancer-global burden, trends, and geographical variations. J Surg Oncol. 2017;115(5):619–12. doi:10.1002/jso.24578.
   PubMed Web of Science ®Google Scholar
• Stintzing S, Modest DP, Rossius L, Lerch MM, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S-E, Heintges T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol. 2016;17(10):1426–1434. doi:10.1016/S1470-2045(16)30269-8.
   PubMed Web of Science ®Google Scholar
• Venook AP, Niedzwiecki D, Lenz H-J, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O’Neil BH, Atkins JN, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS Wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA. 2017;317(23):2392. doi:10.1001/jama.2017.7105.
   PubMed Web of Science ®Google Scholar
• André T, Blons H, Mabro M, Chibaudel B, Bachet J-B, Tournigand C, Bennamoun M, Artru P, Nguyen S, Ebenezer C, et al. Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study. Ann Oncol. 2013;24(2):412–419. doi:10.1093/annonc/mds465.
   PubMed Web of Science ®Google Scholar
• Senft D, Leiserson MDM, Ruppin E, Ronai ZA. Precision oncology: the road ahead. Trends Mol Med. 2017;23(10):874–898. doi:10.1016/j.molmed.2017.08.003.
   PubMed Web of Science ®Google Scholar
• Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-Mtor pathways: cross-talk and compensation. Trends Biochem Sci. 2011;36(6):320–328. doi:10.1016/j.tibs.2011.03.006.
   PubMed Web of Science ®Google Scholar
• Forero A, Han H, Dees E, Wesolowski R, Bardia A, Kabos P, Kern K, Perea R, Pierce K, Houk B, et al. Abstract OT2-07-06: phase Ib study to assess the safety, tolerability, and clinical activity of gedatolisib in combination with palbociclib and either letrozole or fulvestrant in women with metastatic or locally advanced/recurrent breast cancer (B2151009). Cancer Research. 2018;78(4_Supplement):OT2-07-06-OT2-07–06. doi:10.1158/1538-7445.SABCS17-OT2-07-06.
   Web of Science ®Google Scholar
• Forero-Torres A, Han H, Dees EC, Wesolowski R, Bardia A, Kabos P, Layman RM, Lu JM, Kern KA, Perea R, et al. Phase Ib study of gedatolisib in combination with palbociclib and endocrine therapy (ET) in women with estrogen receptor (ER) positive (+) metastatic breast cancer (MBC) (B2151009). J Clin Oncol. 2018;36(15_suppl):1040–1040. doi:10.1200/JCO.2018.36.15_suppl.1040.
   Web of Science ®Google Scholar
• Schettini F, De Santo I, Rea CG, De Placido P, Formisano L, Giuliano M, Arpino G, De Laurentiis M, Puglisi F, De Placido S, et al. CDK 4/6 inhibitors as single agent in advanced solid tumors. Front Oncol. 2018;8:608. doi:10.3389/fonc.2018.00608.
   PubMed Web of Science ®Google Scholar
• O’Hara MH, Edmonds C, Farwell M, Perini RF, Pryma DA, Teitelbaum UR, Giantonio BJ, Damjanov N, Lal P, Feldman MD, et al. Phase II pharmacodynamic trial of palbociclib in patients with KRAS mutant colorectal cancer. J Clin Oncol. 2015;33(3_suppl):626–626. doi:10.1200/jco.2015.33.3_suppl.626.
   Google Scholar
• Wainberg ZA, Shapiro G, Curigliano G, Leong S, Kristeleit RS, Alsina Maqueda M, Britten CD, Milella M, Middleton MR, Olszanski AJ, et al. Phase I study of the PI3K/mTOR inhibitor PF-05212384 in combination with other antitumor agents. J Clin Oncol. 2015;33(15_suppl):2590–2590. doi:10.1200/jco.2015.33.15_suppl.2590.
   Web of Science ®Google Scholar
• Tabernero J, Brega N, Davis C, Gollerkeri A, Pierce K, Suzuki M, Vermette J. 2014. A randomized phase II study (B2151005) of the intravenous phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor PF-05212384 plus irinotecan versus cetuximab plus irinotecan in patients with wild-type KRAS metastatic colorectal cancer (mCRC). J Clin Oncol. 32:TPS3649–TPS3649.
   Web of Science ®Google Scholar
• Lee MS, Helms TL, Feng N, Gay J, Chang QE, Tian F, Wu JY, Toniatti C, Heffernan TP, Powis G, et al. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models. Oncotarget. 2016;7(26):39595–39608. doi:10.18632/oncotarget.9153.
   PubMed Web of Science ®Google Scholar
• Ziemke EK, Dosch JS, Maust JD, Shettigar A, Sen A, Welling TH, Hardiman KM, Sebolt-Leopold JS. Sensitivity of KRAS-Mutant colorectal cancers to combination therapy that cotargets MEK and CDK4/6. Clin Cancer Res. 2016;22(2):405–414. doi:10.1158/1078-0432.CCR-15-0829.
   PubMed Web of Science ®Google Scholar
• Halilovic E, She Q-B, Ye Q, Pagliarini R, Sellers WR, Solit DB, Rosen N. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer Res. 2010;70(17):6804–6814. doi:10.1158/0008-5472.CAN-10-0409.
   PubMed Web of Science ®Google Scholar
• Herrera-Abreu MT, Palafox M, Asghar U, Rivas MA, Cutts RJ, Garcia-Murillas I, Pearson A, Guzman M, Rodriguez O, Grueso J, et al. Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor–positive breast cancer. Cancer Res. 2016;76(8):2301–2313. doi:10.1158/0008-5472.CAN-15-0728.
   PubMed Web of Science ®Google Scholar
• Cretella D, Ravelli A, Fumarola C, La Monica S, Digiacomo G, Cavazzoni A, Alfieri R, Biondi A, Generali D, Bonelli M, et al. The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells. J Exp Clin Cancer Res. 2018;37(1):72. doi:10.1186/s13046-018-0741-3.
   PubMedGoogle Scholar
• Michaloglou C, Crafter C, Siersbaek R, Delpuech O, Curwen JO, Carnevalli LS, Staniszewska AD, Polanska UM, Cheraghchi-Bashi A, Lawson M, et al. Combined Inhibition of mTOR and CDK4/6 is required for optimal blockade of E2F function and long-term growth inhibition in estrogen receptor–positive breast cancer. Mol Cancer Ther. 2018;17(5):908–920. doi:10.1158/1535-7163.MCT-17-0537.
   PubMed Web of Science ®Google Scholar
• Bendell JC, Varghese AM, Hyman DM, Bauer TM, Pant S, Callies S, Lin J, Martinez R, Wickremsinhe E, Fink A, et al. A first-in-human Phase 1 study of LY3023414, an Oral PI3K/mTOR dual inhibitor, in patients with advanced cancer. Clin Cancer Res. 2018;24(14):3253–3262. doi:10.1158/1078-0432.CCR-17-3421.
   PubMed Web of Science ®Google Scholar
• Wainberg ZA, Alsina M, Soares HP, Braña I, Britten CD, Del Conte G, Ezeh P, Houk B, Kern KA, Leong S, et al. A multi-Arm Phase I study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in advanced cancer. Target Oncol. 2017;12(6):775–785. doi:10.1007/s11523-017-0530-5.
   PubMed Web of Science ®Google Scholar
• Goodwin R, Jonker D, Chen E, Kennecke H, Cabanero M, Tsao M-S, Vickers M, Bohemier C, Lim H, Ritter H, et al. A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancer. Invest New Drugs. 2020;38(4):1077–1084. doi:10.1007/s10637-019-00814-3.
   PubMed Web of Science ®Google Scholar
• Tabernero J, Geel RV, Guren TK, Yaeger RD, Spreafico A, Faris JE, Yoshino T, Yamada Y, Kim TW, Bendell JC, et al. Phase 2 results: encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF- mutant colorectal cancer (BRAFm CRC). J Clin Oncol. 2016;34(15_suppl):3544–3544. doi:10.1200/JCO.2016.34.15_suppl.3544.
   PubMed Web of Science ®Google Scholar
• Mallon R, Feldberg LR, Lucas J, Chaudhary I, Dehnhardt C, Santos ED, Chen Z, dos Santos O, Ayral-Kaloustian S, Venkatesan A, et al. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor. Clin Cancer Res. 2011;17(10):3193–3203. doi:10.1158/1078-0432.CCR-10-1694.
   PubMed Web of Science ®Google Scholar
• Pitts TM, Newton TP, Bradshaw-Pierce EL, Addison R, Arcaroli JJ, Klauck PJ, Bagby SM, Hyatt SL, Purkey A, Tentler JJ, et al. Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer. PLos One. 2014;9(11):e113037. doi:10.1371/journal.pone.0113037.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhou L, Zhao S, Dicker DT, El-Deiry WS. The CDK4/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia. Cell Cycle. 2017;16(12):1193–1200. doi:10.1080/15384101.2017.1320005.
   PubMed Web of Science ®Google Scholar
• Koncina H, Rauh L, Rauh, S, Letellier, E. Prognostic and predictive molecular biomarkers for colorectal cancer: updates and challenges. Cancers. 2020;12:319. doi:10.3390/cancers12020319.
   PubMed Web of Science ®Google Scholar
• Iwenofu OH, Lackman RD, Staddon AP, Goodwin DG, Haupt HM, Brooks JSJ. Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy. Mod Pathol. 2008;21(3):231–237. doi:10.1038/modpathol.3800995.
   PubMed Web of Science ®Google Scholar
• El-Salem M, Raghunath PN, Marzec M, Wlodarski P, Tsai D, Hsi E, Wasik MA. Constitutive activation of mTOR signaling pathway in post-transplant lymphoproliferative disorders. Lab Invest. 2007;87(1):29–39. doi:10.1038/labinvest.3700494.
   PubMed Web of Science ®Google Scholar
• Dufner A, Andjelkovic M, Burgering BMT, Hemmings BA, Thomas G. Protein kinase B Localization and activation differentially affect S6 Kinase 1 activity and eukaryotic translation initiation factor 4E-Binding Protein 1 phosphorylation. Mol Cell Biol. 1999;19(6):4525–4534. doi:10.1128/MCB.19.6.4525.
   PubMed Web of Science ®Google Scholar
• Tee AR, Blenis J. mTOR, translational control and human disease. Semin Cell Dev Biol. 2005;16(1):29–37. doi:10.1016/j.semcdb.2004.11.005.
   PubMed Web of Science ®Google Scholar
• Parsons R. Human cancer, PTEN and the PI-3 kinase pathway. Semin Cell Dev Biol. 2004;15(2):171–176. doi:10.1016/j.semcdb.2003.12.021.
   PubMed Web of Science ®Google Scholar
• Vignot S, Faivre S, Aguirre D, Raymond E. Mtor-targeted therapy of cancer with rapamycin derivatives. Ann Oncol. 2005;16(4):525–537. doi:10.1093/annonc/mdi113.
   PubMed Web of Science ®Google Scholar
• Dufner A, Thomas G. Ribosomal S6 Kinase signaling and the control of translation. Exp Cell Res. 1999;253(1):100–109. doi:10.1006/excr.1999.4683.
   PubMed Web of Science ®Google Scholar
• Ferrari S, Bandi HR, Hofsteenge J, Bussian BM, Thomas G. Mitogen-activated 70K S6 kinase. Identification of in vitro 40 S ribosomal S6 phosphorylation sites. J Biol Chem. 1991;266(33):22770–22775. doi:10.1016/S0021-9258(18)54634-2.
   PubMed Web of Science ®Google Scholar
• Setia S, Nehru B, Sanyal SN. Upregulation of MAPK/Erk and PI3K/Akt pathways in ulcerative colitis-associated colon cancer. Biomed Pharmacother. 2014;68(8):1023–1029. doi:10.1016/j.biopha.2014.09.006.
   PubMed Web of Science ®Google Scholar
• Rowinsky EK. Targeting the molecular target of rapamycin (mTOR. Curr Opin Oncol. 2004;16(6):564–575. doi:10.1097/01.cco.0000143964.74936.d1.
   PubMed Web of Science ®Google Scholar
• Petroulakis E, Mamane Y, Le Bacquer O, Shahbazian D, Sonenberg N. mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer. 2006;94(2):195–199. doi:10.1038/sj.bjc.6602902.
   PubMed Web of Science ®Google Scholar
• Kamada Y, Funakoshi T, Shintani T, Nagano K, Ohsumi M, Ohsumi Y. Tor-mediated induction of autophagy via an Apg1 Protein Kinase complex. J Cell Biol. 2000;150(6):1507–1513. doi:10.1083/jcb.150.6.1507.
   PubMed Web of Science ®Google Scholar
• Vora SR, Juric D, Kim N, Mino-Kenudson M, Huynh T, Costa C, Lockerman EL, Pollack SF, Liu M, Li X, et al. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors inhibitors sensitize PIK3CA mutant breast cancer to PI3K Inhibitors. Cancer Cell. 2014;26(1):136–149. doi:10.1016/j.ccr.2014.05.020.
   PubMed Web of Science ®Google Scholar
• Dan S, Yoshimi H, Okamura M, Mukai Y, Yamori T. Inhibition of PI3K by ZSTK474 suppressed tumor growth not via apoptosis but G0/G1 arrest. Biochem Biophys Res Commun. 2009;379(1):104–109. doi:10.1016/j.bbrc.2008.12.015.
   PubMed Web of Science ®Google Scholar
• Dou QP, An B, Will PL. Induction of a retinoblastoma phosphatase activity by anticancer drugs accompanies p53-independent G1 arrest and apoptosis. Proc Natl Acad Sci. 1995;92(20):9019–9023. doi:10.1073/pnas.92.20.9019.
   PubMed Web of Science ®Google Scholar
• Popowski M, Ferguson HA, Sion AM, Koller E, Knudsen E, Van Den Berg CL. Stress and IGF-I differentially control cell fate through Mammalian Target of Rapamycin (mTOR) and Retinoblastoma Protein (pRB). J Biol Chem. 2008;283(42):28265–28273. doi:10.1074/jbc.M805724200.
   PubMed Web of Science ®Google Scholar
• Antonucci LA, Egger JV, Krucher NA. Phosphorylation of the Retinoblastoma protein (Rb) on serine-807 is required for association with bax. Cell Cycle. 2014;13:3611–3617. doi:10.4161/15384101.2014.964093.
   PubMed Web of Science ®Google Scholar
• Egger JV, Lane MV, Antonucci LA, Dedi B, Krucher NA. Dephosphorylation of the Retinoblastoma protein (Rb) inhibits cancer cell EMT via Zeb. Cancer Biol Ther. 2016;17(11):1197–1205. doi:10.1080/15384047.2016.1235668.
   PubMed Web of Science ®Google Scholar
• Mei ZB, Duan CY, Li CB, Cui L, Ogino S. Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysis. Ann Oncol. 2016;27(10):1836–1848. doi:10.1093/annonc/mdw264.
   PubMed Web of Science ®Google Scholar
• Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P, De Dosso S, Mazzucchelli L, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-Targeted monoclonal antibodies. Cancer Res. 2009;69(5):1851–1857. doi:10.1158/0008-5472.CAN-08-2466.
   PubMed Web of Science ®Google Scholar
• Wang Q, Shi Y, Zhou K, Wang L, Yan Z, Liu Y, Xu L, Zhao S, Chu H, Shi T, et al. PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer. Cell Death Disease. 2018;9(7):739. doi:10.1038/s41419-018-0776-6.
   PubMed Web of Science ®Google Scholar
• Mezynski MJ, Farrelly AM, Cremona M, Carr A, Morgan C, Workman J, Armstrong P, McAuley J, Madden S, Fay J, et al. Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer. J Transl Med. 2021;19(1):184. doi:10.1186/s12967-021-02842-1.
   PubMed Web of Science ®Google Scholar
• Elster N, Toomey S, Fan Y, Cremona M, Morgan C, Weiner Gorzel K, Bhreathnach U, Milewska M, Murphy M, Madden S, et al. Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer. Ther Adv Med Oncol. 2018;10:175883591877829. doi:10.1177/1758835918778297.
   Web of Science ®Google Scholar
• O’Shea J, Cremona M, Morgan C, Milewska M, Holmes F, Espina V, Liotta L, O’Shaughnessy J, Toomey S, Madden SF, et al. A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib. Oncotarget. 2017;8(49):85120–85135. doi:10.18632/oncotarget.19461.
   PubMedGoogle Scholar
• Paweletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T, Gillespie JW, Emmert-Buck MR, Roth MJ, Petricoin EF III, Liotta LA. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene. 2001;20(16):1981–1989. doi:10.1038/sj.onc.1204265.
   PubMed Web of Science ®Google Scholar